Therapeutics News and Research

RSS

Akorn enters agreement to acquire minority ownership in Aciex

Akorn, Inc., a niche specialty pharmaceutical company, today announced that it has entered into an agreement to acquire a minority ownership in Westborough, MA, based Aciex Therapeutics Inc., an ophthalmic drug development company with a focus on developing novel therapeutics to treat ocular diseases.

3 Aug 2011

GSK, NPS enter agreement to evaluate ronacaleret in new indications

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.

3 Aug 2011

Lipid nanocarriers in cancer diagnosis and therapy: New book

This book introduces fundamental principles of lipid nanocarriers science relevant to cancer therapy. The first in this field, it fills a need for an accurate, coherent and authoritative introduction to lipid nanocarriers focusing in cancer therapy; both because of the growing popularity of these modern drug delivery systems and also because of the emergent need of dealing with cancer treatment.

2 Aug 2011

BARDA awards contracts for development of drugs for radiation injury to the GI tract

The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

2 Aug 2011

Akorn second quarter revenue grows 59% to $32.1 million

Akorn, Inc., a niche specialty pharmaceutical company, today reported financial results for the second quarter of 2011. The Company also separately announced that it has entered into an agreement to acquire a minority ownership in Westborough, MA, based Aciex Therapeutics Inc., an ophthalmic drug development company with a focus on developing novel therapeutics to treat front-of-eye diseases.

2 Aug 2011

One in six older people likely to have abnormal liver test and die from all causes

One in six people over 75 are likely to have at least one abnormal liver test and those that have two or more are twice as likely to die from cancer and 17 times more likely to die from liver disease, according to research in the August issue of Alimentary Pharmacology and Therapeutics.

2 Aug 2011

Lack of TLR1 surface expression linked with increased susceptibility to tuberculosis

Are you genetically predisposed to tuberculosis? Scientists may now be able to answer this question and doctors may be able to adjust their therapeutic approach based on what they learn. That's because new research presented in the Journal of Leukocyte Biology suggests that two frequent mutations in an immune system gene called TLR1 are responsible for cellular changes that ultimately make us less likely to resist the disease.

2 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system

Hibernation Therapeutics USA, LLC has partnered with B. Braun Medical Inc. to introduce an innovative, low-cost syringe pump delivery system for the administration of its patented Adenocaine Hiberplegia solution, the world's first non-depolarizing cardioplegia.

From B. Braun Melsungen AG 1 Aug 2011

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has completed its Phase I study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

1 Aug 2011

RegenoCELL to open new facility in Panama for treatment of congestive heart failure

RegenoCELL Therapeutics, Inc., a leader in adult stem cell therapy, is pleased to announce it is planning to open another state of the art facility in Panama for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy.

30 Jul 2011

PPTA applauds introduction of 'Preserving Access to Orphan Drugs Act'

The Plasma Protein Therapeutics Association (PPTA) applauds the introduction of bipartisan legislation, the Preserving Access to Orphan Drugs Act (H.R. 2672) and (S. 1423), which will safeguard the development of drugs and therapies that treat patients with rare diseases by eliminating barriers to innovation.

30 Jul 2011

EGT transfers clinical grade lentiviral vector to MSKCC

Errant Gene Therapeutics, LLC, a pioneering boutique drug development firm specializing in Rare Diseases, announced the transfer of its clinical grade lentiviral vector, TNS 9.55.3, to Memorial Sloan Kettering Cancer Center.

29 Jul 2011

New protein discovery could help develop intracellular biologic drugs

Permeon Biologics, a biopharmaceutical company pioneering a novel class of intracellular protein biologics, today announced the discovery of an entirely new class of naturally occurring human supercharged proteins called Intraphilins-.

29 Jul 2011

NIH selects Viamet's novel antifungal compound for inclusion in the TRND program

Viamet Pharmaceuticals, Inc. announced today that one of its novel antifungal compounds has been selected for inclusion in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program.

29 Jul 2011

BTI's IPOXYN data on traumatic shock and ischemia to be presented at XIIIth MGH symposium

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today that experiments performed in the laboratory of Massachusetts General Hospital (MGH) faculty member Warren M. Zapol, MD, Emeritus Anesthetist-in-Chief and Director of the MGH Anesthesia Center for Critical Care Research, on BTI's new oxygen carrier for traumatic shock and ischemia, IPOXYNTM, will be presented at the "XIII International Symposium on Blood Substitutes and Oxygen Therapeutics" to be held July 27th-29th at MGH.

29 Jul 2011

Sorrento receives NIAID Phase I STTR grant to develop vaccines against C. difficile infection

Sorrento Therapeutics, Inc. announced today that it has received a Phase I Small Business Technology Transfer Research grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.

29 Jul 2011

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).

28 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

Therapeutics News and Research

Akorn enters agreement to acquire minority ownership in Aciex

GSK, NPS enter agreement to evaluate ronacaleret in new indications

Lipid nanocarriers in cancer diagnosis and therapy: New book

BARDA awards contracts for development of drugs for radiation injury to the GI tract

Akorn second quarter revenue grows 59% to $32.1 million

One in six older people likely to have abnormal liver test and die from all causes

Lack of TLR1 surface expression linked with increased susceptibility to tuberculosis

Alnylam second quarter revenue decreases to $20.6 million

HT, B.Braun partner to launch Adenocaine Hiberplegia syringe pump delivery system

Positive results from Alnylam's ALN-VSP Phase I trial for liver cancer

RegenoCELL to open new facility in Panama for treatment of congestive heart failure

PPTA applauds introduction of 'Preserving Access to Orphan Drugs Act'

EGT transfers clinical grade lentiviral vector to MSKCC

New protein discovery could help develop intracellular biologic drugs

NIH selects Viamet's novel antifungal compound for inclusion in the TRND program

BTI's IPOXYN data on traumatic shock and ischemia to be presented at XIIIth MGH symposium

Sorrento receives NIAID Phase I STTR grant to develop vaccines against C. difficile infection

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News